Biomedical Engineering Reference
In-Depth Information
tumor-specific antibody fragments. J. Biomol. Screen. 16(1),
90-100.
3. Adams GP, Schier R, McCall AM, Simmons HH, Horak EM,
Alpaugh RK, et al. (2001) High affinity restricts the localiza-
tion and tumor penetration of single-chain fv antibody mol-
ecules. Cancer Res. 61(12), 4750-4755.
4. Lu Y, Yang J, Sega E. (2006) Issues related to targeted
delivery of proteins and peptides. AAPS J. 8(3), E466-E478.
5. Khawli LA, Hu P, Epstein AL. (2008) Cytokine, chemokine,
and co-stimulatory fusion proteins for the immunotherapy of
solid tumors. Handb. Exp. Pharmacol. 181, 291-328.
6. Lorberboum-Galski H. (2011) Human toxin-based recombi-
nant immunotoxins/chimeric proteins as a drug delivery
system for targeted treatment of human diseases. Expert
Opin. Drug Deliv. 8(5), 605-621.
7. Mathew M, Verma RS. (2009) Humanized immunotoxins: a
new generation of immunotoxins for targeted cancer therapy.
Cancer Sci. 100(8), 1359-1365.
8. Hetzel C, Bachran C, Tur MK, Fuchs H, Stocker M. (2009)
Improved immunotoxins with novel functional elements.
Curr. Pharm. Des. 15(23), 2700-2711.
9. Pirie CM, Hackel BJ, Rosenblum MG, Wittrup KD. (2011)
Convergent potency of internalized gelonin immunotoxins
across varied cell lines, antigens, and targeting moieties.
J. Biol. Chem. 286(6), 4165-4172.
10. Shapira A, Benhar I. (2010) Toxin-based therapeutic
approaches. Toxins (Basel) 2(11), 2519-2583.
11. Pastan I, Hassan R, Fitzgerald DJ, Kreitman RJ. (2006)
Immunotoxin therapy of cancer. Nat. Rev. Cancer 6(7),
559-565.
12. Kreitman RJ. (2009) Recombinant immunotoxins containing
truncated bacterial toxins for the treatment of hematologic
malignancies. BioDrugs 23(1), 1-13.
13. Murphy JR. (2011) Mechanism of diphtheria toxin catalytic
domain delivery to the eukaryotic cell cytosol and the cellular
factors that directly participate in the process. Toxins (Basel)
3(3), 294-308.
14. Frankel AE, Rossi P, Kuzel TM, Foss F. (2002) Diphtheria
fusion protein therapy of chemoresistant malignancies. Curr.
Cancer Drug Targets 2(1), 19-36.
15. Weldon JE, Pastan I. (2011) A guide to taming a toxin-
recombinant immunotoxins constructed from Pseudomonas
exotoxin A for the treatment of cancer. FEBS J. 278(23),
4683-4700.
16. Mut M, Sherman JH, Shaffrey ME, Schiff D. (2008)
Cintredekin besudotox in treatment of malignant glioma.
Expert Opin. Biol. Ther. 8(6), 805-812.
17. Moayeri M, Leppla SH. (2009) Cellular and systemic effects
of anthrax lethal toxin and edema toxin. Mol. Aspects Med.
30(6), 439-455.
18. Liu S, Aaronson H, Mitola DJ, Leppla SH, Bugge TH. (2003)
Potent antitumor activity of a urokinase-activated engineered
anthrax toxin. Proc. Natl. Acad. Sci. U.S.A. 100(2), 657-662.
19. Liu S, Netzel-Arnett S, Birkedal-Hansen H, Leppla SH.
(2000) Tumor
metalloproteinase-activated anthrax toxin. Cancer Res.
60(21), 6061-6067.
20. Arora N, Leppla SH. (1994) Fusions of anthrax toxin lethal
factor with shiga toxin and diphtheria toxin enzymatic
domains are toxic to mammalian cells.
Infect. Immun.
62(11), 4955-4961.
21. Brunger AT, Rummel A. (2009) Receptor and substrate
interactions of clostridial neurotoxins. Toxicon 54(5),
550-560.
22. Foster K, Chaddock J. (2010) Targeted secretion inhibitors—
innovative protein therapeutics. Toxins (Basel) 2(12), 2795-
2815.
23. Engedal N, Skotland T, Torgersen ML, Sandvig K. (2011)
Shiga toxin and its use in targeted cancer therapy and imag-
ing. Microbiol. Biotechnol. 4(1), 32-46.
24. McIntosh LM, Barnes JL, Barnes VL, McDonald JR. (2009)
Selective CCR2-targeted macrophage depletion ameliorates
experimental mesangioproliferative glomerulonephritis. Clin.
Exp. Immunol. 155(2), 295-303.
25. Shapira A, Gal-Tanamy M, Nahary L, Litvak-Greenfeld D,
Zemel R, Tur-Kaspa R, et al. (2011) Engineered toxins
“zymoxins” are activated by the HCV NS3 protease by
removal of an inhibitory protein domain. PLoS ONE 6(1),
e15916.
26. Petersson K, Forsberg G, Walse B. (2004) Interplay between
superantigens and immunoreceptors. Scand. J. Immunol.
59(4), 345-355.
27. Shaw DM, Connolly NB, Patel PM, Kilany S, Hedlund G,
Nordle O, et al. (2007) A phase II study of a 5T4 oncofoetal
antigen tumour-targeted superantigen (ABR-214936) therapy
in patients with advanced renal cell carcinoma. Br. J. Cancer
96(4), 567-574.
28. Forsberg G, Skartved N-J, Wallen-Ohman M, Nyhlen HC,
Behm K, Hedlund G, et al. (2010) Naptumomab estafenatox,
an engineered antibody-superantigen fusion protein with
low toxicity and reduced antigenicity. J. Immunother. 33
(5), 492-499.
29. Stirpe F, Battelli MG. (2006) Ribosome-inactivating proteins:
progress and problems. Cell. Mol. Life Sci. 63(16), 1850-
1866.
30. Cizeau J, Grenkow DM, Brown JG, Entwistle J, MacDonald
GC. (2009) Engineering and biological characterization of
VB6-845, an anti-EpCAM immunotoxin containing a T-cell
epitope-depleted variant of
the plant
toxin bouganin.
J. Immunother. 32(6), 574-584.
31. Polito L, Bortolotti M, Pedrazzi M, Bolognesi A. (2011)
Immunotoxins and other conjugates containing saporin-s6 for
cancer therapy. Toxins (Basel) 3(6), 697-720.
32. Lombardi A, Bursomanno S, Lopardo T, Traini R, Colombatti
M, Ippoliti R, et al. (2010) Pichia pastoris as a host for secretion
of toxic saporin chimeras. FASEB J. 24(1), 253-265.
33. Endo Y. (1988) Mechanism of action of ricin and related
toxins on the inactivation of eukaryotic ribosomes. Cancer
Treat. Res. 37, 75-89.
34. Schindler J, Gajavelli S, Ravandi F, Shen Y, Parekh S,
Braunchweig I, et al. (2011) A phase I study of a combination
cell-selective
cytotoxicity
of matrix
Search WWH ::
Custom Search